読み込み中
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
前日終値
$5.00
+$0.05 · +1.01%
日中の時刻はETです。市場データは遅延する場合があります。
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
日中レンジ
現在 $5.00
52週レンジ
現在 $5.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
75
割安
センチメント
71
強気
リスク
65
高リスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
日中レンジ
現在 $5.00
52週レンジ
現在 $5.00
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.50
上昇余地（310.00%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5895.99万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3283.06万0.04%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1886.93万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1152.42万0.08%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO965.12万0.05%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB963.74万0.09%108.2億 USD0.44%$206.49+3.00%
State Street SPDR S&P Pharmaceuticals ETFXPH712.02万1.54%4.62億 USD0.35%$64.65+1.60%
Schwab U.S. Small-Cap ETFSCHA692.52万0.03%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
